178 related articles for article (PubMed ID: 34654826)
21. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
[TBL] [Abstract][Full Text] [Related]
22. Gains and losses of CD8, CD20 and CD56 expression in tumor stroma-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and lymphocytes from tumor draining lymph nodes in serous papillary ovarian carcinoma patients.
Papadopoulos N; Kotini A; Cheva A; Jivannakis T; Manavis J; Alexiadis G; Lambropoulou M; Vavetsis S; Tamiolakis D
Eur J Gynaecol Oncol; 2002; 23(6):533-6. PubMed ID: 12556098
[TBL] [Abstract][Full Text] [Related]
23. Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma.
Shi JY; Gao Q; Wang ZC; Zhou J; Wang XY; Min ZH; Shi YH; Shi GM; Ding ZB; Ke AW; Dai Z; Qiu SJ; Song K; Fan J
Clin Cancer Res; 2013 Nov; 19(21):5994-6005. PubMed ID: 24056784
[TBL] [Abstract][Full Text] [Related]
24. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
25. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
[TBL] [Abstract][Full Text] [Related]
26. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease.
Serafini M; Manganini M; Borleri G; Bonamino M; Imberti L; Biondi A; Golay J; Rambaldi A; Introna M
Hum Gene Ther; 2004 Jan; 15(1):63-76. PubMed ID: 14965378
[TBL] [Abstract][Full Text] [Related]
27. CD20
Lee AYS
Inflamm Res; 2022 Nov; 71(10-11):1181-1189. PubMed ID: 35951029
[TBL] [Abstract][Full Text] [Related]
28. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
29. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
[TBL] [Abstract][Full Text] [Related]
30. CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype.
Mao H; Lafont BA; Igarashi T; Nishimura Y; Brown C; Hirsch V; Buckler-White A; Sadjadpour R; Martin MA
J Virol; 2005 Dec; 79(23):14887-98. PubMed ID: 16282488
[TBL] [Abstract][Full Text] [Related]
31. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
32. Proinflammatory CD20
Ochs J; Nissimov N; Torke S; Freier M; Grondey K; Koch J; Klein M; Feldmann L; Gudd C; Bopp T; Häusser-Kinzel S; Weber MS
Sci Transl Med; 2022 Mar; 14(638):eabi4632. PubMed ID: 35353539
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein regulates trafficking of CD8(+) T cells to the brain parenchyma.
Kooij G; Kroon J; Paul D; Reijerkerk A; Geerts D; van der Pol SM; van Het Hof B; Drexhage JA; van Vliet SJ; Hekking LH; van Buul JD; Pachter JS; de Vries HE
Acta Neuropathol; 2014 May; 127(5):699-711. PubMed ID: 24429546
[TBL] [Abstract][Full Text] [Related]
34. CD20+ T cell numbers are decreased in untreated HIV-1 patients and recover after HAART.
Förster F; Singla A; Arora SK; Schmidt RE; Jacobs R
Immunol Lett; 2012 Aug; 146(1-2):74-8. PubMed ID: 22677201
[TBL] [Abstract][Full Text] [Related]
35. Cognate antigen directs CD8+ T cell migration to vascularized transplants.
Walch JM; Zeng Q; Li Q; Oberbarnscheidt MH; Hoffman RA; Williams AL; Rothstein DM; Shlomchik WD; Kim JV; Camirand G; Lakkis FG
J Clin Invest; 2013 Jun; 123(6):2663-71. PubMed ID: 23676459
[TBL] [Abstract][Full Text] [Related]
36. Mouse CD20 expression and function.
Uchida J; Lee Y; Hasegawa M; Liang Y; Bradney A; Oliver JA; Bowen K; Steeber DA; Haas KM; Poe JC; Tedder TF
Int Immunol; 2004 Jan; 16(1):119-29. PubMed ID: 14688067
[TBL] [Abstract][Full Text] [Related]
37. Aberrant recruitment and activation of T cells in diabetic nephropathy.
Moon JY; Jeong KH; Lee TW; Ihm CG; Lim SJ; Lee SH
Am J Nephrol; 2012; 35(2):164-74. PubMed ID: 22286547
[TBL] [Abstract][Full Text] [Related]
38. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
[TBL] [Abstract][Full Text] [Related]
39. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
van Meerten T; Rozemuller H; Hol S; Moerer P; Zwart M; Hagenbeek A; Mackus WJ; Parren PW; van de Winkel JG; Ebeling SB; Martens AC
Haematologica; 2010 Dec; 95(12):2063-71. PubMed ID: 20851867
[TBL] [Abstract][Full Text] [Related]
40. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line.
Abdollahpour-Alitappeh M; Hashemi Karouei SM; Lotfinia M; Amanzadeh A; Habibi-Anbouhi M
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1-8. PubMed ID: 29523024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
